The pharmacokinetics of nelfinavir in HIV-1-infected children

Therapeutic Drug Monitoring

Volumn 24, Issue 4, 2002, Pages 487-491

  Van Heeswijk, Rolf P G ^a   Scherpbier, Henriëtte J ^a   De Koning, Linda A ^a   Heymans, Hugo S A ^a   Lange, Joep M A ^a   Beijnen, Jos H ^a   Hoetelmans, Richard M W ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Children; HIV 1; Nelfinavir; Pharmacokinetics

Indexed keywords

LAMIVUDINE; NELFINAVIR; STAVUDINE;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; MALE; NELFINAVIR; POWDERS; STAVUDINE; TABLETS;

EID: 0036337845     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200208000-00004     Document Type: Article

References (19)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Antiretroviral therapy in adults: Updated recommendations of the international AIDS Society - USA Panel
4. Clinical pharmacokinetics in infants and children, a reappraisal
5. Cytochrome P450 3A: Ontogeny and drug disposition
6. Nelfinavir, an update of its use in HIV infection
7. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate
8. Preliminary experiences with triple therapy including nelfinavir and two protease inhibitors in previously untreated HIV-infected children
9. Nelfinavir pharmacokinetics in HIV-infected children: A comparison of twice daily and three times daily dosing
10. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations
11. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
12. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps
13. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
14. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection
15. Drug interactions of HIV protease inhibitors
16. Nelfinavir pharmacokinetics in stable HIV positive children; the effect of weight and a comparison of tid and bid dosing
17. Lack of pharmacokinetic interaction between nelfinavir and nevirapine
18. Long-term comparison of bid and tid dosing of nelfinavir (nelfinavir) in combination with stavudine (d4T) and lamivudine (3TC) in HIV patients
19. Twice a day (BID) dosing of nelfinavir when used as part of a highly active antiretroviral therapy (HAART): Experience in pediatric HIV/AIDS